BG Medicine (NASDAQ: BGMD) is a publicly traded diagnostics company focused on the development and commercialization of novel cardiovascular tests to address significant unmet medical needs, improve patient outcomes and reduce healthcare costs. The Company has two products: the BGM Galectin-3® test for use in patients with chronic heart failure is available in the United States and Europe; and the CardioSCORE™ test for the risk prediction of major cardiovascular events is expected to be launched in Europe in the first half of 2013. BG Medicine is a Flagship VentureLabs™ company.

Noubar Afeyan is a Founder and serves on the Board of Directors and Stéphane Bancel is Executive Chairman of the Board.